Evaluation of new putative tumor markers for melanoma.

Published

Journal Article

BACKGROUND: The early diagnosis of recurrent melanoma can contribute to better outcome if the disease can be surgically resected or if the metastases are responsive to systemic therapies. Lipid-associated sialic acid (LASA-P) and the S-100 protein (S-100) were evaluated as tumor markers for melanoma with the goal of early detection of recurrence. METHODS: Sixty-seven patients were identified who had levels of S-100 and LASA-P drawn during their clinical course. A multivariate regression analysis was performed to determine the significance of the serum markers in relation to other prognostic factors for melanoma. RESULTS: After a median follow-up of 30 months, 58 patients had recurrences, and 49 patients died of disease. LASA-P elevation was not associated with the time to recurrence (p = 0.2176) or survival (p = 0.2507). S-100 positivity was a significant predictor of recurrence (p < 0.0001) and survival (p = 0.0059). The median time to recurrence for S-100-positive and S-100-negative patients was 7.6 and 33.8 months, respectively. The median survival time was 59.2 months for S-100-negative patients and 29.6 months for patients positive for S-100. CONCLUSIONS: Serum S-100 shows significant correlations to both time to recurrence and survival and could be useful in the clinical detection of malignant melanoma.

Full Text

Duke Authors

Cited Authors

  • Miliotes, G; Lyman, GH; Cruse, CW; Puleo, C; Albertini, PA; Rapaport, D; Glass, F; Fenske, N; Soriano, T; Cuny, C; Van Voorhis, N; Reintgen, D

Published Date

  • November 1996

Published In

Volume / Issue

  • 3 / 6

Start / End Page

  • 558 - 563

PubMed ID

  • 8915488

Pubmed Central ID

  • 8915488

International Standard Serial Number (ISSN)

  • 1068-9265

Digital Object Identifier (DOI)

  • 10.1007/bf02306089

Language

  • eng

Conference Location

  • United States